Cochrane · systematic review · CD011132

Aminoadamantanes versus other antiviral drugs for chronic hepatitis C

Lamers, MH, Broekman, M, Drenth, JPH, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library

Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 66.7%Low 2 · 33.3%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Comparison

Population: patients with chronic hepatitis C.
6 questions
OutcomeEffectEvidenceStatus / GRADE
All‐cause mortality or liver‐related morbidity
RR 0.98 [0, 248.89]4 studies · 427 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Adverse events
RR 0.56 [0.27, 1.16]4 studies · 427 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Failure of sustained virological response Absence of clearance of HCV RNA from the blood 6 months after treatment
RR 1.14 [1.07, 1.22]4 studies · 427 participantsLow
Downgraded: risk of bias, imprecision, inconsistency
Failure of end of treatment virological response Absence of clearance of HCV RNA from the blood at end of treatment
RR 1.2 [1.05, 1.36]3 studies · 309 participantsLow
Downgraded: risk of bias, imprecision, inconsistency
Failure of normalisation of ALT at end of treatment
RR 2.02 [1.07, 3.82]1 study · 29 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Failure of normalisation of ALT at end of
RR 1.31 [1.05, 1.63]2 studies · 92 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency